Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 28, 2024 13:24 ET | Source: KuicK Research

Bispecific Trispecific Tetraspecific Multispecific Antibodies Market Size Clinical Trials Approved Antibody Sales Price Insight Antibodies Market By Region Indication Companies

Delhi, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Global Multispecific Antibodies Market, Drug Sales, Price and Clinical Trials Insight 2029 Report Highlights: Global and Regional Market AnalysisGlobal...
December 07, 2020 08:00 ET | Source: TeneoBio, Inc

Teneobio Reports Initial Data from a Phase I Study of TNB-383B in Relapsed Refractory Multiple Myeloma

NEWARK, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, reported...
June 08, 2020 08:00 ET | Source: TeneoBio, Inc

Teneobio Enters a Research Collaboration and Licensing Agreement to Develop Next Generation Engineered Cell Therapies with Intellia Therapeutics

NEWARK, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc. announced that it has entered into a research collaboration and licensing agreement with Intellia Therapeutics, a CRISPR/Cas9...
September 30, 2019 08:00 ET | Source: TeneoBio, Inc

Teneobio Licenses Oncology Multispecific Product to Janssen

NEWARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that...
July 15, 2019 08:00 ET | Source: TeneoBio, Inc

Teneobio Doses First Patient in Phase 1 Study of TNB-383B for the Treatment of Patients with Multiple Myeloma

NEWARK, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc. a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that...
July 09, 2018 08:00 ET | Source: TeneoBio, Inc

Teneobio Announces Research Collaboration with Janssen to Develop Multispecific Antibodies for Oncology

MENLO PARK, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Teneobio, Inc., a next generation multi-specific antibody therapeutics company, announced today the initiation of a research collaboration and...
January 08, 2018 08:00 ET | Source: TeneoBio, Inc

Teneobio Announces a Strategic Alliance with TESARO to Develop the Next Generation of Immuno-Oncology, Multispecific Antibodies

MENLO PARK, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Teneobio, Inc., a next generation multi-specific antibody therapeutics company announced today the initiation of a research collaboration and...